Skeletal Muscle Relaxants Uses, Efficacy, and Side Effects

Skeletal muscle relaxants are a heterogeneous sort of medications. As a class, they are structurally and pharmacologically diverse. Muscle relaxants are inured to to treat two different types of underlying conditions: spasticity from more elevated motor neuron syndromes muscular pain or spasms from outside musculoskeletal conditions. Although muscle relaxants have by usage been classified into one group, the Food and Drug Management (FDA) has approved only a few medications in this class for treatment of spasticity. The residue are approved for treatment of musculoskeletal conditions.

Drugs classified as skeletal muscle relaxants tabulate:
baclofen (Lioresal)
carisoprodol (Soma)
chlorzoxazone (Paraflex)
cyclobenzaprine (Flexeril)
dantrolene (Dantrium)
metaxalone (Skelaxin)
methocarbamol (Robaxin)
orphenadrine (Norflex)
tizanidine (Zanaflex)

Muscle relaxants for treatment of spasticity Spasticity is a solemn of increased muscular tone with exaggeration of the tendon reflexes. Some of the more routine conditions associated with spasticity and requiring treatment include multiple sclerosis, spinal rope injury, traumatic brain injury, cerebral palsy, and poststroke syndrome. In tons patients with these conditions, spasticity can be disabling and painful with a significant effect on functional ability and quality of life. The upper motor neuron syndrome is a complex of signs and symptoms that can be associated with exaggerated cutaneous reflexes, autonomic hyperreflexia, dystonia, contractures, paresis, want of dexterity, and fatigability. Spasticity from the upper motor neuron syndrome can denouement from a variety of conditions affecting the cortex or spinal cord.
Only baclofen, dantrolene, and tizanidine are approved for treatment of spasticity. There is free evidence that baclofen and tizanidine are roughly equivalent for efficacy in patients with spasticity, but deficient evidence to determine the efficacy of dantrolene compared to baclofen or tizanidine. Tizanidine is associated with more dry declaim and baclofen with more weakness.

Muscle relaxants for treatment of musculoskeletal conditions Muscle fit is defined as a sudden involuntary contraction of one or more muscle groups and is on the whole an acute condition associated with muscle strain (partial scurry of a muscle) or sprain (partial or complete rupture of a ligament). Common musculoskeletal conditions causing tenderness and muscle spasms classify fibromyalgia, tension headaches, myofascial pain syndrome, and mechanical low bet on a support pain or neck pain. If muscle spasm is present in these conditions, it is cognate to local factors involving the affected muscle groups. The skeletal muscle relaxants carisoprodol, chlorzoxazone, cyclobenzaprine, metaxalone, methocarbamol, and orphenadrine are approved for treatment of musculoskeletal disorders.
Clinical studies come, that cyclobenzaprine, carisoprodol, orphenadrine, and tizanidine are effective compared to placebo in patients with musculoskeletal conditions (at bottom acute back or neck pain). Cyclobenzaprine has been evaluated in the most clinical trials and has unfailingly been found to be effective.
Efficacy
Most studies have shown the skeletal muscle relaxants to be more functioning than placebo in the treatment of acute painful musculoskeletal disorders and muscle twitch, while efficacy was less consistent when treating chronic disorders. When muscle relaxants were acquainted with alone, they were not consistently superior to simple analgesics in relieving grief. When the skeletal muscle relaxants were used in combination with analgesics, suffering relief is superior to either agent used alone. Studies possess suggested that these drugs are effective, have tolerable side effects, and can be an adjunct in the treatment of bitter musculoskeletal conditions with associated muscle spasm. No studies have documented superior efficacy of one skeletal muscle relaxant over another.

Side Effects and Adverse reactions
All skeletal muscle relaxants may induce sedation (drowsiness, dizziness). Baclofen may cause inexorable central nervous system depression with cardiovascular collapse and respiratory loss. Dantrolene has a potential for hepatotoxicity. Overt hepatitis has been most as often as not observed between the third and twelfth months of therapy. Endanger of hepatic injury appears to be greater in women, in patients past 35 years of age and in patients taking other medications in totalling to dantrolene. Carisoprodol has some potential for dependence and withdrawal symptoms. Cyclobenzaprine, closely mutual to the tricyclic antidepressants, causes the expected lethargy and anticholinergic side effects, and may obtain some toxicity in overdose and in combination with other substances.
Tizanidine may occasion low blood pressure, but this may be controlled by starting with a low dose and increasing it piece by piece. The drug may rarely cause liver damage. Methocarbamol and chlorzoxazone may motivate harmless color changes in urine - orange or reddish-purple with chlorzoxazone and purple, brown, or unripe with methocarbamol. The urine will return to its normal color when the unfaltering stops taking the medicine.